Skip to main content

Table 1 Patient characteristics of men diagnosed with non-metastatic prostate cancer receiving radical treatment according to the Cambridge Prognostic Group (CPG) classification

From: Risk stratification for prostate cancer management: value of the Cambridge Prognostic Group classification for assessing treatment allocation

CPGCriteria10-year risk of dying from prostate cancer without treatment* (%)10-year risk of dying from prostate cancer with treatment* (%)
1Gleason score 6 (grade group 1)
AND PSA < 10 ng/ml
AND stages T1–T2
4.21.2
2Gleason score 3 + 4 = 7 (grade group 2)
OR PSA 10–20 ng/ml AND stages T1–T2
4.72.3
3Gleason score 3 + 4 = 7 (grade group 2)
AND PSA 10–20 ng/ml
AND stages T1–T2
OR
Gleason score 4 + 3 = 7 (grade group 3)
AND stages T1–T2
15.13.2
4One of the following:
Gleason score 8 (grade group 4)
OR PSA > 20 ng/ml
OR stage T3
N/A**5.8
5Any combination of Gleason score 8 (grade group 4), PSA > 20 ng/ml or stage T3
OR Gleason score 9–10 (grade group 5)
OR stage T4
N/A**13.7
  1. *Mortality is taken from Gnanapragasam et al. [3]
  2. *No reliable data is available for untreated men with CPG4 or CPG5